CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for...

The trial is expected to enroll up to 300 patients in , CTI reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the PERSIST-2 trial, which is a written agreement between CTI and the FDA regarding the planned design, endpoints and statistical analysis approach of the trial to be used in support of a ... (more)

http://ift.tt/1eTSWJh